Related Experiment Video

Updated: Oct 4, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment

R C Stein1

  • 1The Ludwig Institute for Cancer Research and Department of Oncology, Royal Free and University College London Medical School, 91 Riding House Street, London W1W 7BS, UK. rstein@ludwig.ucl.ac.uk

Endocrine-Related Cancer
|September 22, 2001
PubMed

Insights

Phosphoinositide 3-kinases (PI3-kinases) regulate cell functions and are implicated in cancer. Isoform-selective PI3-kinase inhibitors show promise as targeted anticancer drugs, offering an alternative to non-selective inhibitors.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Phosphoinositide 3-kinases (PI3-kinases) are crucial lipid kinases involved in fundamental cellular processes.
  • These processes include cell proliferation, survival, metabolism, and motility.
  • Aberrant PI3-kinase activity is increasingly recognized as a significant factor in cancer development.

Purpose of the Study:

  • To explore the role of PI3-kinase family members in cancer.
  • To investigate the potential of isoform-selective PI3-kinase inhibitors as anticancer therapeutics.

Main Methods:

  • Review of existing scientific literature on PI3-kinases and cancer.
  • Analysis of emerging evidence for functional specialization among PI3-kinase isoforms.

Main Results:

  • Strong evidence supports the involvement of specific PI3-kinase members in oncogenesis.
  • Emerging data suggests functional differences between PI3-kinase isoforms.

Conclusions:

  • Targeting specific PI3-kinase isoforms may offer a more precise therapeutic strategy than using non-selective inhibitors like wortmannin and LY294002.
  • Isoform-selective PI3-kinase inhibitors represent a promising avenue for novel anticancer drug development.

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...